Sunshine Biopharma Stock Performance
| SBFM Stock | USD 2.28 0.05 2.24% |
The entity has a beta of 1.9, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sunshine Biopharma will likely underperform. At this point, Sunshine Biopharma has a negative expected return of -0.35%. Please make sure to validate Sunshine Biopharma's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Sunshine Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sunshine Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.24 | Five Day Return 16.92 | Year To Date Return (27.16) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:20 | Dividend Date 2020-04-06 | Last Split Date 2024-08-08 |
1 | Disposition of tradable shares by Keller Andrew Mark of Sunshine Biopharma subject to Rule 16b-3 | 12/26/2024 |
2 | Insider Trading | 01/13/2025 |
3 | Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer | 01/15/2025 |
4 | Disposition of 2591500 shares by Steve Slilaty of Sunshine Biopharma at 0.05 subject to Rule 16b-3 | 01/28/2025 |
5 | Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian 200 Million Market | 03/10/2025 |
6 | Acquisition by Camille Sebaaly of 129468927 shares of Sunshine Biopharma subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 21.8 M |
Sunshine |
Sunshine Biopharma Relative Risk vs. Return Landscape
If you would invest 300.00 in Sunshine Biopharma on December 23, 2024 and sell it today you would lose (72.00) from holding Sunshine Biopharma or give up 24.0% of portfolio value over 90 days. Sunshine Biopharma is currently does not generate positive expected returns and assumes 4.4558% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Sunshine, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sunshine Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sunshine Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sunshine Biopharma, and traders can use it to determine the average amount a Sunshine Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0786
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SBFM |
Estimated Market Risk
| 4.46 actual daily | 39 61% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sunshine Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sunshine Biopharma by adding Sunshine Biopharma to a well-diversified portfolio.
Sunshine Biopharma Fundamentals Growth
Sunshine Stock prices reflect investors' perceptions of the future prospects and financial health of Sunshine Biopharma, and Sunshine Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sunshine Stock performance.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | (5.46 M) | ||||
| Shares Outstanding | 2.71 M | ||||
| Price To Earning | 1.07 X | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 0.19 X | ||||
| Revenue | 24.09 M | ||||
| Gross Profit | 10.14 M | ||||
| EBITDA | (3.82 M) | ||||
| Net Income | (4.51 M) | ||||
| Cash And Equivalents | 41.74 M | ||||
| Cash Per Share | 2.21 X | ||||
| Total Debt | 657.71 K | ||||
| Debt To Equity | 8.98 % | ||||
| Current Ratio | 401.11 X | ||||
| Book Value Per Share | 12.52 X | ||||
| Cash Flow From Operations | (8.78 M) | ||||
| Earnings Per Share | (127.90) X | ||||
| Market Capitalization | 6.18 M | ||||
| Total Asset | 27.35 M | ||||
| Retained Earnings | (63.91 M) | ||||
| Working Capital | 19.34 M | ||||
| Current Asset | 23 K | ||||
| Current Liabilities | 277 K | ||||
About Sunshine Biopharma Performance
By examining Sunshine Biopharma's fundamental ratios, stakeholders can obtain critical insights into Sunshine Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sunshine Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 119.58 | 141.65 | |
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
Things to note about Sunshine Biopharma performance evaluation
Checking the ongoing alerts about Sunshine Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sunshine Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21. | |
| Latest headline from MacroaxisInsider: Acquisition by Camille Sebaaly of 129468927 shares of Sunshine Biopharma subject to Rule 16b-3 |
- Analyzing Sunshine Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sunshine Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Sunshine Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sunshine Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sunshine Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sunshine Biopharma's stock. These opinions can provide insight into Sunshine Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.